Non-peptide δ opioid agonists and antagonists (Part II)

Bibliography

• KIEFFER BL, BEFORT K, GAVRIAUX-RUFF C, HIRTH CG: The 5-opioid receptor: isolation of a cDNA by expres-sion cloning and pharmacological characterization. Proc. Natl. Acad. ScL USA (1992) 89:12048–12052.
   PubMed Web of Science ®Google Scholar
• EVANS CJ, KEITH DE, JR., MORRISON H, MAGENDZO K, EDWARDS RH: Cloning of a delta opioid receptor by functional expression. Science (1992) 258:1952–1955.
   Google Scholar
• SATOH M, MINAMI M: Molecular pharmacology of the opioid receptors. Pharmac. Ther. (1995) 68:343–364.
   PubMed Web of Science ®Google Scholar
• ZENZ M, WILLWEBER-STRUMPF A: Opiophobia and can-cer pain in Europe. Lancet (1993) 341:1075–1076.
   PubMed Web of Science ®Google Scholar
• DIONNE RA, DOBBINS KR, HARGREAVES KN: Evaluation of a kappa opioid agonist, spiradoline, in comparison to morphine and placebo in the oral surgery model. Pharmacol. Ther. (1991) 49:183.
   Google Scholar
• PETERS GR, GAYLOR S: Human central nervous system(CNS) effects of a selective x opioid agonist. Gun. Phar-macol. Ther. (1989) 45:130.
   Web of Science ®Google Scholar
• STEIN C, MILLAN MJ, SHIPPENBERG TS, PETER K, HERZ H:Peripheral opioid receptors mediating antinocicep-tion in inflammation. Evidence for involvement of mu, delta and kappa receptors. J. Pharm. Exp. Ther. (1989) 248:1269–1275.
   PubMed Web of Science ®Google Scholar
• HYLDEN JLK, THOMAS DA, IADAROLA MJ, NAHIN RL,DUBNER R: Spinal opioid analgesic effects are en-hanced in a model of unilateral inflammation/hyper-algesia: possible involvement of noradrenergic mechanisms. Eur.J. Pharmacol (1991) 194:135–143.
   PubMedGoogle Scholar
• POZZI O, ANGELICI O, PETRONE G et al.: SB 235863, anew non peptidic delta opioid receptor agonist with antihyperalgesic activity. 28th Annual Meeting of Society for Neuroscience. Los Angeles, USA (1998). 352.16
   Google Scholar
• STANFA LC, SULLIVAN AF, DICKENSON AH: Alterationsin neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced in-flammation. Pain (1992) 50:345–354.
   PubMed Web of Science ®Google Scholar
• MOULIN DE, MAX MB, KAIKO RF et al.: The analgesic effi-cacy of intrathecal D-A1a2-D-Leu5-enkephalin in cancer patients with chronic pain. Pain (1985) 23:213–221.
   PubMed Web of Science ®Google Scholar
• RAPAKA RS, PORRECA F: Development of delta opioid peptides as nonaddicting analgesics. Pharm. Res. (1991) 8:1–8.
   PubMed Web of Science ®Google Scholar
• DONDIO G, RONZONI S, PETRILLO P: Non-peptide 8 opioid agonists and antagonists. Exp. Opin. Ther. Pat-ents. (1997) 7:1075–1098.
   Web of Science ®Google Scholar
• DONDIO G, RONZONI S, EGGLESTON DS et al: Discov-ery of a novel class of substituted pyrrolooctahydroi-soquinolines as potent and selective .5 opioid agonists, based on an extension of the message-address con-cept. J. Med. Chem. (1997) 40:3192–3198.
   Google Scholar
• DONDIO G, RONZONI S, PETRILLO P, DESJARLAIS RL, RAVEGLIA LF: Pyrrolooctahydroisoquinolines as po-tent and selective .5 opioid receptor ligands: SAR analy-sis and docking studies. Bioorg. Med. Chem. Lett. (1997) 7:2967–2972.
   Google Scholar
• DONDIO G, RONZONI S, GATTI PA et al: Development of novel analgesics acting through the selective activa-tion of the 8 opioid receptor. 216th ACS National Meet-ing Boston, USA (1998). MEDI206.
   Google Scholar
• CALDERON SN, RICE KC, ROTHMAN RB et al.: Probes for narcotic receptor mediated phenomena. 23. Synthe-sis, opioid receptor binding, and bioassay of the highly selective .5 agonist (+)-4-[(aR)-a-((25,5R)-4-ally1--2,5-dimethyl-1-piperaziny1)-3-methoxybenzyll-N,N-diethylbenzamide (SNC 80) and related novel nonpep-tide .5 opioid receptor ligands. J. Med. Chem. (1997) 40:695–704.
   Google Scholar
• WILD KD, MCCORMICK J, BILSKY EJ et al.: Antinocicep-tive actions of BW373U86 in the mouse. J. Pharmacol. Exp. Ther. (1993) 267:858–865.
   PubMed Web of Science ®Google Scholar
• WEI ZY, DELORME D, GAWELL L et al: Development of highly potent and selective nonpeptidic delta opioid receptor agonists. 9th RSC-SCI Medicinal Chemistry Sym-posium. Cambridge, UK (1997). P23.
   Google Scholar
• KATSURA Y, ZHANG X, HOMMA K et al.: Probes for nar-cotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (a-piperaziny-lbenzyObenzamides as novel, highly selective .5 opioid receptor agonists. J. Med. Chem. (1997) 40:2936–2947.
   Google Scholar
• LIAO S, ALFARO-LOPEZ J, SHENDEROVICH MD et al: De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the opioid receptor. J. Med. Chem. (1998) 41:4767–4776.
   PubMedGoogle Scholar
• PETRILLO P, ARTICO M, DONDIO G et al.: In vitro charac-terization of new potent and .5 selective pyrrolomor-phinans. XXVII International Narcotics Research Conference. Garmisch-Partenkirchen, Germany (1998). Fr21.
   Google Scholar
• RONZONI S, ARTICO M, ARTINO A et al: SAR studies on a new class of potent and selective 8 ligands, the pyrrolo morphinans X)( VII International Narcotics Research Con-ference. Garmisch-Partenkirchen, Germany (1998). Fr22.
   Google Scholar
• GAO P, LARSON DL, PORTOGHESE PS: Synthesis of 7-arylmorphinans. Probing the 'address' requirements for selectivity at opioid 8 receptors. J. Med. Chem. (1998) 41:3091–3098.
   Google Scholar
• TIAN X, DERSCH CM, MCCULLOUGH K, HOREL R, ROTH-MAN RB, RICE KC: Synthesis and biological activities of 14-alkyl opioid ligands. 216th ACS National Meeting. Boston, USA (1998). MEDI 296.
   Google Scholar
• ANANTHAN S, JOHNSON CA, CARTER RL eta].: Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. J. Med. Chem. (1998) 41:2872–2881.
   Google Scholar
• KSHIRSAGAR TA, FANG X, PORTOGHESE PS: 14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at .5 opioid receptors. J. Med. Chem. (1998) 41:2657–2660.
   Google Scholar
• KUBOTA H, ROTHMAN RB, DERSCH C, MCCULLOUGH K, PINTO J, RICE KC: Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives. Bioorg. Med. Chem. Lett. (1998) 8:799–804.
   PubMedGoogle Scholar
• PORTOGHESE PS, SULTANA M, NAGASE H, TAKEMORI AE: A highly selective 81-opioid receptor antagonist: 7-benzylidennaltrexone. J. Med. Chem. (1992) 218:195–196.
   Google Scholar
• OHKAWA S, PORTOGHESE PS: 7-Arylidenenaltrexones as selective 81 opioid receptor antagonists. J. Med. Chem. (1998) 41:4177–4180.
   PubMedGoogle Scholar
• FANG X, LARSON DL, PORTOGHESE PS: 7 - Spirobenzocyclohexyl derivatives of naltrexone, oxy-morphone, and hydromorphone as selective opioid receptor ligands. J. Med. Chem. (1997) 40:3064–3070.
   PubMedGoogle Scholar
• SU Y-F, MCNUTT W, CHANG K-J: Delta-opioid ligands re-verse alfentanil-induced respiratory depression but not antinociception. J. Pharmacol. Exp. Ther. (1998) 287:815–823.
   PubMedGoogle Scholar
• ZAKI PA, BILSKY EJ, VANDERAH TW et al.: Opioid recep-tor types and subtypes: the 8 receptor as a model. Ann. Rev. Pharmacol. Toxicol (1996) 36:379–401.
   PubMed Web of Science ®Google Scholar
• UHL GR, CHILDERS S, PASTERNAK G: An opiate-receptor gene family reunion. Trends Neurosci. (1994) 17:89–93.
   PubMed Web of Science ®Google Scholar
• KIM DS, CHIN H, KLEE WA: Agonist regulation of the ex-pression of the delta opioid receptor in NG108-15 cells. FEBS Lett. (1995) 376:11–14.
   PubMed Web of Science ®Google Scholar
• ROSSI GC, SU W, LEVENTHAL L, SU H, PASTERNAK GW: Antisense mapping DOR-1 in mice: further support for .5 receptor subtypes. Brain Res. (1997) 753:176–179.
   Google Scholar
• ANTONIJEVIC I, MOUSA SA, SCHAFER M, STEIN C: Per-ineurial defect and peripheral opioid analgesia in in-flammation. J. Neurosci. (1995) 15:165–172.
   PubMed Web of Science ®Google Scholar
• HASSAN AH, ABLEITNER A, STEIN C, HERZ A: Inflamma-tion of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience (1993) 55:185–195.
   PubMed Web of Science ®Google Scholar
• DESMEULES JA, KAYSER V, GUILBAUD G: Selective opioid receptor agonists modulate mechanical allo-dynia in an animal model of neuropathic pain. Pain (1993) 53:277–285.
   PubMedGoogle Scholar
• HAO J-X, YU W, WIESENFELD-HALLIN Z, XU X-J: Treat-ment of chronic allodynia in spinally injured rats: ef-fects of intrathecal selective opioid receptor agonists. Pain (1998) 75:209–217.
   PubMedGoogle Scholar
• BINGHAM S, DAVEY PT, DONDIO G et al.: The delta ago-nist, SB-235863A reverses thermal hyperalgesia in a rat model of established neuropathic pain. 28th Annual Meeting of Society for Neuroscience. Los Angeles, USA (1998). 352.15.
   Google Scholar
• DICKENSON AH: Plasticity: implications for opioid and other pharmacological interventions in specific pain states. Behav. Brain Sci. (1997) 20:392–403.
   Google Scholar
• ••Comprehensive review on possible role of DOR in chronicpain states.
   Google Scholar
• BHARGAVA HN, VILLAR VM, CORTIJO J, MORCILLO EJ: Binding of [311][D-Ala2, MePhe4,Gly-o151enkephalin, [311][D-Pen2,D-Pen5]enkephalin, and [311]U-69,593 to airway and pulmonary tissues of normal and sensi-tized rats. Peptides (1997) 18: 1603-1608.
   Google Scholar
• RAMNARINE SI, YU-CHI L, ROGERS DF: Neuroregulation of mucus secretion by opioid receptors and KATp and BKC channel in ferret trachea in vitro. Br. J. Pharmacol (1998) 123:1631–1638.
   PubMed Web of Science ®Google Scholar
• NISHIMURA E, BUCHAN AM, MCINTOSH CH: Autoradio-graphic localization of mu- and delta-type opioid re-ceptors in the gastrointestinal tract of the rat and guinea pig. Gastroenterology (1986) 91:1084–1094.
   PubMedGoogle Scholar
• GYIRES K, RONAI AZ, TOTH G, DARULA Z, FORST S: Analysis of the role of delta opioid receptors in gastro-protection in the rat. Life Sci. (1997) 60:1337–1347.
   PubMedGoogle Scholar
• NOWAK JE, GOMEZ-FLORES R, CALDERON SN, RICE KC,WEBER RJ: Rat natural killer cell, T cell and macro-phage functions after intracerebroventricular injec-tion of SNC 80. J. Pharmacol. Exp. Ther. (1998) 286:931–937.
   PubMedGoogle Scholar
• TANG J-L, LIPKOWSKI AW, SPECTER S: Inhibitory effectof biphalin and AZT on murine Friend leukemia virus infection in vitro. Int. J. Immunopharmacol (1998) 20:457–466.
   PubMedGoogle Scholar
• SHARP BM, GEKKER G, LI MD, CHAO CC, PETERSON PK:8-opioid suppression of human immunodeficiency virus-1 expression in T cells (Jurkat). Biochem. Pharma-col. (1998) 56:289–292.
   PubMed Web of Science ®Google Scholar
• •This work suggests new possible clinical utility of 8 agonists as additional therapeutic agents in antiviral approach to HIV-1 infection.
   Google Scholar
• SEZEN SF, KENIGS VA, KAPUSTA DR: Renal excretory re-sponses produced by the delta opioid agonist, BW373U86, in conscious rats. J. Pharmacol. Exp. Ther. (1998) 287:238–245.
   PubMed Web of Science ®Google Scholar
• CHIEN S, OELTGEN PR, DIANA JN, SALLEY RK: Extensionof tissue survival time in multiorgan block prepara-tion with a delta opioid DADLE (ED-Ala2, D-Leu51-e-nkephalin). J. Thorac. Cardiovasc. Surg. (1994) 107:964–967.
   PubMed Web of Science ®Google Scholar
• SCHULTZ JJ, HSU AK, GROSS GJ: Ischemic precondition-ing and morphine-induced cardioprotection involve the delta (6)-opioid receptor in the intact rat heart. J. Mol. Cell. Cardiol. (1997) 29:2187–2195.
   PubMed Web of Science ®Google Scholar
• SCHULTZ JJ, HSU AK, GROSS GJ: Ischemic precondition-ing in the intact rat heart is mediated by 61- but not µ-or x-opioid receptors. Circulation (1998) 97:1282–1289.
   PubMed Web of Science ®Google Scholar
• SCHULTZ JJ, HSU AK, NAGASE H, GROSS GJ: TAN-67, a61-opioid receptor agonist, reduces infarct size via ac-tivation of G110 proteins and KATP channels. Am. J. Physiol. (1998) 274:H909–H914.
   Google Scholar
• •First paper describing the cardioprotective activity of a non-peptide 8 agonist during ischaemia.
   Google Scholar
• MANSOUR A, FOX CA, AKIL H, WATSON SJ: Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. (1995) 18:22–29.
   PubMed Web of Science ®Google Scholar
• KONIG M, ZIMMER AM, STEINER H et al.: Pain responses,anxiety and aggression in mice deficient in pre-proenkephalin. Nature (1996) 383:535–538.
   PubMed Web of Science ®Google Scholar
• PICKAR D, CUTLER NR, NABER D, POST RM, PERT CB, BUNNEY WE, JR.: Plasma opioid activity in manic-depressive illness. Lancet (1980) 1:937.
   Google Scholar
• TEJEDOR-REAL P, MICO JA, SMADJA C, MALDONADO R, ROQUES BP, GIBERT-RAHOLA JG: Involvement of 8-opioid receptors in the effects induced by endoge-nous enkephalins on learned helplessness model. Eur. J. Pharmacol. (1998) 354:1–7.
   PubMedGoogle Scholar
• TSAO L-I, LADENHEIM B, ANDREWS AM, CHIUEH CC, CA-DET JL, SU T-P: Delta opioid peptide [D-Ala2, D-Leu5len-kephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species. J. Pharmacol. Exp. Ther. (1998) 287:322–331.
   PubMedGoogle Scholar
• TORTELLA FC: Endogenous opioid peptides and epi-lepsy: quieting the seizing brain? Trends in Pharmacol Sci. (1988) 9:366–372.
   Google Scholar
• TORTELLA FC, ECHEVARRIA E, ROBLES L, MOSBERG HI,HOLADAY JW: Anticonvulsant effects on mu (DAGO) and delta (DPDPE) enkephalins in rats. Peptides (1988) 9:1177–1181.
   PubMedGoogle Scholar
• KOTLINSKA J, LANGWINSKI R: Audiogenic seizures dur-ing ethanol withdrawal can be blocked by a delta opioid agonists. Drug Akohol Depend. (1986) 18:361–367.
   PubMedGoogle Scholar
• KOIDE S, ONISHI H, YAMAGAMI S, KAWAKITA Y: Effectsof morphine and D-A1a2-D-Leu5-enkephalin in the seizure-susceptible El mouse. Neurochem Res. (1992) 17:779–783.
   PubMedGoogle Scholar
• ONISHI H, KOIDE S, YAMAGAMI S, KAWAKITA Y: Devel-opmental and regional alteration of methionine enkephalin-like immunoreactivity in seizure-susceptible El mouse brain. Neurochem Res. (1990) 15:83–87.
   PubMedGoogle Scholar
• CHENG JG, XIE XK: A study on opioid peptides in CSF ofpatients with epilepsy. Epilepsy Res. (1990) 6:141–145.
   PubMedGoogle Scholar
• MADAR I, LESSER RP, KRAUSS G et al.: Imaging of .5- andµ-opioid receptors in temporal lobe epilepsy by posi-tron emission tomography. Ann. Neurol (1997) 41:358–367.
   Google Scholar
• •This work demonstrates the involvement of the DOR in epi-leptic focus in patients.
   Google Scholar
• CAMPA MJ, SCHREIBER G, BEPLER G et al: Characteriza-tion of 6 opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res. (1996) 56:1695–1701.
   PubMedGoogle Scholar
• SCHREIBER G, CAMPA MJ, PRABHAKAR S, O'BRIANT K, BEPLER G, PATZ EF, JR.: Molecular characterization of the human 8 opioid receptor in lung cancer. Anticancer Res. (1998) 18:1787–1792.
   Google Scholar
• HENRY B, BROTCHIE JM: Potential of opioid antago-nists in the treatment of levodopa-induced dyskine-sias in Parkinson's disease. Drug Aging (1996) 9:149–158.
   PubMedGoogle Scholar
• TRABUCCHI M, BASSI S, FRATTOLA L: Effect of naloxoneon the 'on-off syndrome in patients receiving long-term levodopa therapy. Arch. Neurol (1982) 39:120–121.
   PubMedGoogle Scholar
• BERTOLUCCI M, PEREGO C, DE SIMONI MG: Interleukin-6 is differently modulated by central opioid receptor subtypes. Am. J. Physic)]. (1997) 273:R956–R959.
   Google Scholar
• •Interesting work demonstrating the involvement of 8 opioid antagonists in central and peripheral IL-1 immunomodulation.
   Google Scholar
• OHKAWA S, DIGIACOMO B, LARSON DL, TAKEMORI AE, PORTOGHESE PS: 7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for 8 opioid receptors. J. Med. Chem. (1997) 40:1720–1725.
   PubMedGoogle Scholar
• LINNER KM, STICKNEY BJ, QUIST HE, SHARP BM, POR-TOGHESE PS: The 61-opioid receptor antagonist, 7-benzylspiroindanylnaltrexone, prolongs renal allo-graft survival in a rat model. Eur. J. Pharmacol (1998) 354:R3–R5.
   Google Scholar
• PERRY VH, ANDERSSON P-B, GORDON S: Macrophages and inflammation in the central nervous system. Trends Neurosci. (1993) 16:268–273.
   PubMedGoogle Scholar
• MCGEER EG, MCGEER PL: The future use of complement inhibitors for the treatment of neurological diseases. Drugs (1998) 55:739–746.
   PubMedGoogle Scholar
• GIULIAN D: Immune response and dementia. Ann. NY Acad. Sci. (1997) 835:91–110.
   PubMedGoogle Scholar
• MILLIGAM CE, WEBSTER L, PIROS ET, EVANS CJ, CUN-NINGHAM TJ, LEVITT P: Induction of opioid receptor-mediated macrophage chemotactic activity after neo-natal brain injury. J. Immunol (1995) 154:6571–6581.
   PubMedGoogle Scholar
• FROEHLICH JC: Genetic factors in alcohol self-administration. J. Clin. Psychiat. (1995) 56\(Suppl. 7):15–23.
   Google Scholar
• KRISHNAN-SARIN S, JING SL, KURTZ DL et al.: The deltaopioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (1995) 120:177–185.
   PubMedGoogle Scholar
• FROEHLICH JC, BADIA-ELDER NE, ZINK RW, MCCULLOUGH DE, PORTOGHESE PS: Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. J. Pharmacol. Exp. Ther. (1998) 287:284–292.
   PubMedGoogle Scholar
• •Interesting paper demonstrating the mechanism of action of 8 opioid antagonists in alcohol aversion.
   Google Scholar
• DE WAELE J-P, GIANOULAKIS C: Characterization of the µ and .5 opioid receptors in the brain of the C57BL/6 and DBA/2 mice selected for their differences in volun-tary ethanol consumption. Clin. Exp. Res. (1997) 21:754–762.
   Google Scholar
• SUZUKI T, TSUJI M, MORI T, MISAWA M, NAGASE H: In-volvement of 61 and 82 receptor subtypes in the devel-opment of physical dependence on morphine in mice. Pharmacol. Biochem. Behav. (1997) 57:293–299.
   PubMedGoogle Scholar
• HEPBURN MJ, LITTLE PJ, GINGRAS J, KUHN CM: Differen-tial effects of naltrindole on morphine-induced toler-ance and physical dependence in rats. J. Pharmacol Exp. Ther. (1997) 281:1350–1356.
   PubMed Web of Science ®Google Scholar